



## Types of treatment

### Laser coagulation

Standard treatment in 2010



Treatment is provided in **specialized centers**

108 EUR (in 2018)  
Fully reimbursed from  
Health Insurance Company  
Code 8730

< or >

160 EUR  
by the patient,  
if you are self-payer



*Waiting list for  
the treatment is  
long, it usually  
takes 6 months*

Different types of lasers available to patients – **yellow, black, green**

### Drug treatment

Standard treatment in 2020

#### Anti-VEGF drugs

Ranibizumab

Aflibercept

Bevacizumab

Avastin (Bevacizumab)  
is used by  
1/3 of providers.



## Reimbursement mechanism

If the provider has a contract with Health insurance Company:



**no limits**



**no copayment**

IAD (Intravenous application of drugs) **reimbursement 107-109 EUR**  
+  
Anti-VEGF drugs

Active substance	Brand name	Usage	Reimbursement
Ranibizumab	Lucentis 10mg/ml	Intravitreal 1,65 mg	636,31 EUR
Aflibercept	Eylea 40 mg/ml	Intravitreal 40 mg/ml	668,62 EUR

Source: ŠUKL, 2022



## Good practice

- Wide coverage of diagnostics for DME
- Avastin "off-label" allowed
- Specialized centers to carry out treatments
- Each injection paid separately



## Room for improvement

- Avastin could be used even more as it is now.

*Access to healthcare services in the context of financing mechanisms. The case of ophthalmology*



Start: 01-11-2021  
End: 30-04-2023  
Project ID: Ns22120107  
Programme: Visegrad Fund